Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 671 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Complications Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

Bladder Morphology Using 2 Different Catheter Designs

NCT03108079
View directory record Official record
Conditions
Urologic Injuries, Urologic Diseases, Bladder Infection, Urinary Tract Infections, Mucosal Inflammation, Mucosal Infection, Bladder Injury, Catheter-Related Infections, Catheter Complications, Catheter; Infection (Indwelling Catheter), Pelvic Floor Disorders, Urinary Incontinence
Interventions
Cystosure Urinary Access System, Foley Catheter
Device
Lead sponsor
The Pelvic Floor Institute
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01381094
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548, Placebo
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Pine Bluff, Arkansas • Covina, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Not listed Phase 2 Interventional

Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis

NCT05096065
View directory record Official record
Conditions
Endometriosis
Interventions
Leuprolide Oral Tablet - 120 mg - QD- Treatment A, Leuprolide Oral Tablet - 80 mg - QD - Treatment B, Leuprolide Oral Tablet - 60 mg - QD - Treatment C, Leuprolide Oral Tablet - 60 mg - BID - Treatment D, Leuprolide Oral Tablet - 40 mg - BID - Treatment E
Drug
Lead sponsor
Enteris BioPharma Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
4
States / cities
Sarasota, Florida • Columbus, Ohio • Norfolk, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

PROMMO Trial: Oral Misoprostol vs IV Oxytocin

NCT04478942
View directory record Official record
Conditions
Premature Rupture of Membrane, Induction of Labor Affected Fetus / Newborn
Interventions
Misoprostol Oral Product, Intravenous Oxytocin
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Terminated Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

NCT00283842
View directory record Official record
Conditions
Diabetic Neuropathies, Pain
Interventions
DVS SR, Placebo
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
51
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

NCT01190475
View directory record Official record
Conditions
Endometriosis
Interventions
Active treatment with a high dose of BGS649, Active treatment with a low dose of BGS649, Placebo treatment to blind study
Drug
Lead sponsor
Mereo BioPharma
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Not applicable Interventional

Self-Administered 2-Hour Oral Glucose Tolerance Test

NCT06099509
View directory record Official record
Conditions
Gestational Diabetes, Postpartum Disorder, Gestational Diabetes Mellitus in Pregnancy
Interventions
Self-administered oral glucose tolerance test
Other
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available

Oral Ondansetron Versus Transdermal Granisetron (Sancuso) for Women With Cervical, Endometrial or Vaginal Cancer Receiving Pelvic Chemoradiation

NCT01536392
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Granisetron, Ondansetron, Questionnaires, Study Drug Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Intravenous Iron vs. Oral Iron Supplementation for Postpartum Anemia

NCT05047211
View directory record Official record
Conditions
Anemia, Iron Deficiency, Delivery Complication
Interventions
Ferrous sulfate, Iron dextran
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01305200
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Eosinophilic Leukemia, Chronic Myelomonocytic Leukemia, Chronic Neutrophilic Leukemia, de Novo Myelodysplastic Syndromes, Disseminated Neuroblastoma, Juvenile Myelomonocytic Leukemia, Mucositis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Childhood Rhabdomyosarcoma, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Recurrent/Refractory Childhood Hodgkin Lymphoma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
supersaturated calcium phosphate rinse, placebo, questionnaire administration, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
31
States / cities
Arcadia, California • Duarte, California • Oakland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

NCT00317239
View directory record Official record
Conditions
Anemia
Interventions
Ferrous Sulfate tablets, Ferric Carboxymaltose (FCM)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Jul 20, 2026, 7:20 PM EDT
Withdrawn Not applicable Interventional

A Mobile Application for Post-op Analgesic Consumption

NCT03197311
View directory record Official record
Conditions
Tooth Extraction Status Nos, Post Operative Pain, Patient Satisfaction, Narcotic Use, Mobile App
Interventions
Mobile app
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis

NCT05213624
View directory record Official record
Conditions
Kidney Disease, Chronic
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
20
States / cities
Huntsville, Alabama • San Francisco, California • South Gate, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 3 Interventional

A Study of Nevirapine for the Prevention of HIV Transmission From Mothers to Their Babies

NCT00000869
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

NCT00006396
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional

A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain

NCT00375960
View directory record Official record
Conditions
Pain, Diabetic Neuropathies
Interventions
V3381, Placebo
Drug
Lead sponsor
Vernalis (R&D) Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Walnut Creek, California • Clearwater, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2007 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Not applicable Interventional

POEM Anterior Versus Posterior Approach

NCT02454335
View directory record Official record
Conditions
Achalasia
Interventions
Peroral Endoscopic Myotomy
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 1, 2018 · Synced Jul 20, 2026, 7:20 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot Trial Investigating Every Other Day Dosing of Oral Iron in Premature Infants (IQONic)

NCT06555315
View directory record Official record
Conditions
Very Low Birth Weight Infant, Premature Infants, Anemia of Prematurity, Iron Deficiency, Anaemia in Children, Extremely Low Birth Weight
Interventions
6 mg/kg of oral iron as ferrous sulfate administered every other day., 6 mg/kg of oral iron as ferrous sulfate administered every day.
Dietary Supplement
Lead sponsor
CHRISTUS Health
Other
Eligibility
26 Weeks to 32 Weeks
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Not applicable Interventional Results available

Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer

NCT02589938
View directory record Official record
Conditions
Radiation-Induced Xerostomia, Head and Neck Cancer, Radiation Toxicity, Oral Complications of Chemotherapy and Head/Neck Radiation
Interventions
Standard Oral Hygiene, Standard Oral Hygiene + True Acupuncture, Standard Oral Hygiene + Sham Acupuncture
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
36
States / cities
Burbank, California • San Francisco, California • San Jose, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Recruiting Phase 3 Interventional

Peri-operative Oral Pain Control Following Buccal Graft Urethroplasty

NCT05300685
View directory record Official record
Conditions
Urethral Stricture, Male
Interventions
Standard Buccal Harvest, Basic buccal procedure + Long acting local, Basic buccal procedure + Buccal block
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Francisco, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function

NCT00501462
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
4
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Jul 20, 2026, 7:20 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Surgical Myomectomy Followed by Oral Myfembree Versus Standard of Care Trial (SOUL)

NCT05538689
View directory record Official record
Conditions
Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
Interventions
Myfembree Oral Product
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
6
States / cities
Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 3 Interventional Results available

Oral Progesterone for Prevention of Preterm Birth

NCT01180296
View directory record Official record
Conditions
Preterm Birth
Interventions
oral micronized progesterone, Identical Placebo tablet
Drug
Lead sponsor
Fetal Medicine Foundation
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 20, 2026, 7:20 PM EDT